Announcements Trials

Browse Landscape

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 3 Breast 3 Thoracic 2 Tumor-Agnostic 1

Conditions

Interventions

pembrolizumab 18 Nivolumab 18 Gemcitabine 9 Ipilimumab 8 Cisplatin 8 Carboplatin 8 Capecitabine 8 Paclitaxel 6 Cetuximab 6 atezolizumab 5 Irinotecan 5 Docetaxel 5 Cyclophosphamide 5 Bevacizumab 5 avelumab 4 Trastuzumab 4 Fluorouracil 4 trametinib 3 spartalizumab 3 Specimen Handling 3 Pemetrexed 3 Leucovorin 3 Everolimus 3 Dexamethasone 3 Biopsy 3 urelumab 2 toripalimab 2 tislelizumab 2 ribociclib 2 repotrectinib 2

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

Clinical Trials

1 trials

Recent Start date Enrollment

Phase 1/2 × patritumab deruxtecan × Tumor-Agnostic × Clear all

NCT06941272 2026-05-12

MK-9999-01C

Merck Sharp & Dohme LLC

Phase 1/2 Recruiting

Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon ⚡